These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 17179823

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
    Nielsen VG, Kirklin JK, George JF.
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
    [Abstract] [Full Text] [Related]

  • 4. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 5. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN.
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [Abstract] [Full Text] [Related]

  • 6. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
    Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN.
    J Clin Invest; 1997 May 15; 99(10):2323-7. PubMed ID: 9153272
    [Abstract] [Full Text] [Related]

  • 9. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH, Rijken DC.
    Thromb Haemost; 2004 Mar 15; 91(3):473-9. PubMed ID: 14983222
    [Abstract] [Full Text] [Related]

  • 10. Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity.
    Malayaman SN, Cohen JB, Machovec KA, Bernhardt BE, Arkebauer MR, Nielsen VG.
    Blood Coagul Fibrinolysis; 2011 Jun 15; 22(4):345-8. PubMed ID: 21330914
    [Abstract] [Full Text] [Related]

  • 11. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul 15; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 12. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2009 Apr 15; 20(3):191-6. PubMed ID: 19657316
    [Abstract] [Full Text] [Related]

  • 13. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B, Livnat T, Lubetsky A, Tamarin I, Budnik I, Einav Y, Martinowitz U.
    Blood Coagul Fibrinolysis; 2012 Jul 15; 23(5):370-8. PubMed ID: 22498982
    [Abstract] [Full Text] [Related]

  • 14. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 15; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 15. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2010 Sep 15; 21(6):584-7. PubMed ID: 20683324
    [Abstract] [Full Text] [Related]

  • 16. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG, Kirklin JK.
    Blood Coagul Fibrinolysis; 2008 Dec 15; 19(8):793-800. PubMed ID: 19002046
    [Abstract] [Full Text] [Related]

  • 17. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
    Mosnier LO, Meijers JC, Bouma BN.
    Thromb Haemost; 2001 Oct 15; 86(4):1040-6. PubMed ID: 11686322
    [Abstract] [Full Text] [Related]

  • 18. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J, Hudecek J, Kubisz P.
    Vnitr Lek; 2004 Jan 15; 50(1):36-44. PubMed ID: 15015228
    [Abstract] [Full Text] [Related]

  • 19. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y, Honda Y.
    J Thromb Thrombolysis; 2019 Jul 15; 48(1):103-110. PubMed ID: 30972711
    [Abstract] [Full Text] [Related]

  • 20. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
    Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN.
    Thromb Haemost; 1998 Nov 15; 80(5):829-35. PubMed ID: 9843179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.